✦ LIBER ✦

Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma

✍ Scribed by Andrés J. M. Ferreri; Marta Bruno Ventre; Giovanni Donadoni; Chiara Cattaneo; Luca Fumagalli; Marco Foppoli; Silvia Mappa; Silvia Govi; Massimo Di Nicola; Giuseppe Rossi; Umberto Tirelli; Federico Caligaris-Cappio; Michele Spina; Alessandro Re

Book ID: 117940120
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 108 KB
Volume: 159
Category: Article
ISSN: 0007-1048
DOI: 10.1111/bjh.12020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

50 Efficacy of new short-term high inten

50 Efficacy of new short-term high intensive protocol BL-M-04 for adult patients with Burkitt lymphoma

✍ E. Baryakh; S. Kravchenko; E. Zvonkov; A. Kremenetskaya; T. Obuhova; J. Popova; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Efficacy and short-term safety of a new

Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia

✍ William Insull Jr.; Michael Koren; Jean Davignon; Dennis Sprecher; Helmut Schrot 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 119 KB

Phase 2a Randomized Controlled Trial of

Phase 2a Randomized Controlled Trial of Short-Term Activity, Safety, and Pharmacokinetics of a Novel Nonnucleoside Reverse Transcriptase Inhibitor, RDEA806, in HIV-1-Positive, Antiretroviral-Naive Subjects

✍ Moyle, G.; Boffito, M.; Stoehr, A.; Rieger, A.; Shen, Z.; Manhard, K.; Sheedy, B 📂 Article 📅 2010 🏛 American Society for Microbiology 🌐 English ⚖ 618 KB

273 SHORT TERM SAFETY, TOLERABILITY, PHA

273 SHORT TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ACTIVITY OF GS-9450, A SELECTIVE CASPASE INHIBITOR, IN PATIENTS WITH CHRONIC HCV INFECTION

✍ M.P. Manns; E. Lawitz; A.I.M. Hoepelman; H.J. Choi; J.Y. Lee; M. Cornpropst; W. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 65 KB

Efficacy and safety of short-term adalim

Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial

✍ J. HINOJOSA; F. GOMOLLÓN; S. GARCÍA; G. BASTIDA; J. L. CABRIADA; C. SARO; D. CEB 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 557 KB